

Report of Organizational Actions Affecting Basis of Securities

OMB No. 1545-0123

► See separate instructions.

Part I Reporting Issuer

1 Issuer's name Acuren Corporation		2 Issuer's employer identification number (EIN) 66-1076867	
3 Name of contact for additional information Andrew Shen	4 Telephone No. of contact (281) 223-7650	5 Email address of contact andrew.shen@acuren.com	
6 Number and street (or P.O. box if mail is not delivered to street address) of contact 14434 Medical Complex Drive, Suite 100		7 City, town, or post office, state, and ZIP code of contact Tomball, Texas 77377	
8 Date of action August 4, 2025		9 Classification and description Common Stock and cash	
10 CUSIP number 00510N102	11 Serial number(s)	12 Ticker symbol TIC	13 Account number(s)

Part II Organizational Action Attach additional statements if needed. See back of form for additional questions.

14 Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ► [See attachment.](#)

15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ► [See attachment.](#)

16 Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ► [See attachment.](#)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► See attachment.

18 Can any resulting loss be recognized? ► See attachment.

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► **See attachment.**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Signature ▶  Date ▶ September 2, 2025

Print your name ▶ Kristin Schultes Title ▶ Chief Financial Officer

Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
Firm's name ▶			Firm's EIN ▶	
Firm's address ▶			Phone no.	

**Acuren Corporation (“Acuren”)
(successor to NV5 Global, Inc. (“NV5”))
EIN: 66-1076867
Attachment to Form 8937**

The information contained herein is being provided pursuant to the requirements of Section 6045B of the Internal Revenue Code of 1986, as amended (the “Code”), which requires certain issuers of securities, or acquirors of such securities, to report certain organizational actions that affect the U.S. tax basis of those securities in the hands of stockholders who are U.S. persons and the quantitative effect of such organizational actions on the basis of such securities. The information contained herein does not constitute tax advice and does not purport to be complete or describe the tax consequences that may apply to particular persons or categories of persons that held stock of NV5 prior to the Merger (as defined below). No ruling has been (or will be) sought from the U.S. Internal Revenue Service (the “IRS”) with respect to the organizational action reported herein and the U.S. Internal Revenue Service is not bound by the information set forth herein. Former holders of NV5 Common Stock are encouraged to consult their independent tax advisors regarding the particular consequences of the Merger to them (including the applicability and effect of all federal, state, local and non-U.S. laws and possible changes in law that might affect the tax consequences described in this Form 8937 and this Attachment to Form 8937). Capitalized terms that are not defined in this Attachment to Form 8937 have the meaning assigned to them under the Merger Agreement (as defined below).

Line 14

On August 4, 2025 (the “Closing Date”), Acuren completed the acquisition of NV5 by way of two mergers with direct, wholly-owned subsidiaries of Acuren as follows (i) Ryder Merger Sub I, Inc. (“Merger Sub I”) merged with and into NV5 with NV5 continuing as the surviving entity (the “First Merger”), and (ii) immediately following the First Merger, NV5 merged with and into Ryder Merger Sub II, Inc. (“Merger Sub II”) with Merger Sub II continuing as the surviving entity (the “Second Merger” and, together with the First Merger, the “Merger”). The Merger was carried out pursuant to an Agreement and Plan of Merger among Acuren, Merger Sub I, Merger Sub II, and NV5, dated May 14, 2025 (the “Merger Agreement”).

As a result of the Merger, each issued and outstanding share of common stock, par value \$0.01 per share, of NV5 (“NV5 Common Stock”) was, subject to the terms and conditions of the Merger Agreement, converted into \$10.00 in cash and 1.1523 shares of common stock, par value \$0.0001 per share, of Acuren (“Acuren Common Stock”).

Holders of NV5 Common Stock were not issued fractional shares of Acuren Common Stock in the Merger, but instead received cash in lieu of any fractional share of Acuren Common Stock. A U.S. holder that received cash in lieu of a fractional share of Acuren Common Stock generally is treated as having received the fractional share pursuant to the Merger, and then as having sold to Acuren that fractional share of Acuren Common Stock for cash.

Additional details regarding the Merger and a copy of the Merger Agreement can be found in the Current Report on Form 8-K filed by Acuren with the U.S. Securities and Exchange Commission on August 4, 2025 (File No. 001-42524), which is available at www.sec.gov.

Line 15

The Merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Code. Provided the Merger qualifies as a reorganization within the meaning of Section 368(a) of the Code, the material U.S.

federal income tax consequences to a U.S. holder whose shares of NV5 Common Stock are exchanged in the Merger generally should be as follows:

- a U.S. holder generally should not recognize any realized loss but should recognize any realized gain as a result of the Merger equal to the lesser of (i) the excess, if any, of (A) the sum of the fair market value of Acuren Common Stock (including any fractional share of Acuren Common Stock deemed received and redeemed for cash) and the amount of cash consideration (excluding the amount of any cash in lieu of a fractional share of Acuren Common Stock) received by such U.S. holder pursuant to the Merger over (B) such U.S. holder's adjusted tax basis in the NV5 Common Stock surrendered pursuant to the Merger, and (ii) the amount of cash consideration (excluding the amount of any cash in lieu of a fractional share of Acuren Common Stock) received by such U.S. holder pursuant to the Merger;
- each U.S. holder's aggregate tax basis in the shares of Acuren Common Stock received in the Merger (including any fractional share of Acuren Common Stock deemed received and redeemed for cash) generally should equal such U.S. holder's aggregate adjusted tax basis in the shares of NV5 Common Stock surrendered in the Merger, less the amount of cash consideration (excluding the amount of any cash in lieu of a fractional share of Acuren Common Stock) received pursuant to the Merger, plus any gain, if any, recognized as a result of the Merger (other than any gain recognized in respect of cash received in lieu of a fractional share of Acuren Common Stock); and
- the holding period of the shares of Acuren Common Stock received by a U.S. holder in the Merger (including any fractional share deemed received and redeemed for cash) generally should include such U.S. holder's holding period for the shares of NV5 Common Stock surrendered in the Merger.

If a U.S. holder holds different blocks of NV5 Common Stock (generally, NV5 Common Stock acquired on different dates or at different prices), such U.S. holder should consult its tax advisor with respect to the determination of the tax bases and/or holding periods of the particular shares of Acuren Common Stock received in the Merger.

Line 16

See Line 15 above for a general description of the U.S. federal income tax consequences of the Merger for a U.S. stockholder, including the determination of such stockholder's aggregate basis in any Acuren Common Stock received. For this purpose, the taxable gain (if any) recognized is determined by reference to the fair market value of Acuren Common Stock and the amount of cash received in the Merger. Although U.S. federal income tax rules do not specify how to determine fair market value, one possible approach is to use the volume-weighted average price (VWAP) of Acuren Common Stock for the ten full consecutive trading days ending on and including the Business Day prior to the Closing Date in accordance with the Merger Agreement, which was \$11.28. Acuren is not taking a position as to the appropriate method for determining the fair market value of each share of Acuren Common Stock received in the Merger on this Form 8937. Other approaches to determine fair market value may also be possible and a U.S. holder of NV5 Common Stock should consult its independent tax advisor regarding the appropriate method for determining fair market value.

Line 17

The Merger is intended to qualify as a reorganization within the meaning of Section 368(a) of the Code. In general, the income tax consequences to the U.S. stockholders are determined under Sections 354, 356, 358, and 368 of the Code.

Line 18

As described in Line 15, provided the Merger qualifies as a reorganization within the meaning of Section 368(a) of the Code, a U.S. holder generally should not recognize loss on the exchange.

Line 19

The Merger and resulting stock exchange were effective August 4, 2025. The stock basis adjustments are taken into account in the tax year of the stockholder during which the Merger occurred; therefore, the reportable tax year for calendar year taxpayers is the 2025 calendar year.